Abstract
Vaccination still represents the most efficient and inexpensive strategy in the control of hepatitis B virus (HBV) infection. However, about 10% of the population vaccinated with the current S yeast-derived vaccine fail to induce an adequate immune response. Our group has developed a new-generation hepatitis B vaccine candidate composed by the three surface proteins of the HBV. Here we describe the methods to develop and characterize a stable CHO-K1 recombinant cell line able to produce and secrete hepatitis B subviral envelope particles (HBV-SVPs) containing L and M glycoproteins in addition to S glycoprotein. In addition, Western blot and immunogold electron microscopy techniques to evaluate the size, morphology, and composition of the particles are explained. Finally, immunization protocols are described in order to study the immunogenicity of HBV-SVPs and the ability of the antibodies triggered by these particles to recognize the binding site of HBV with the hepatocyte.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Razavi-Shearer D, Razavi H (2018) Global prevalence of hepatitis B virus infection and prevention of mother-to-child transmission. Lancet Gastroenterol Hepatol 3:598
World Health Organization (2017) Global hepatitis report. WHO, Geneva
Bray F, Ferlay J, Soerjomataram I (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
Yuen M, Chen D, Dusheiko G, Janssen H, Lau D, Locarnini S, Peters M, Lai C (2018) Hepatitis B virus infection. Nat Rev Dis Primers 4:18035
Gerlich W (2015) Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol 204:39–55
Pan L, Zhang L, Zhang W, Wu X, Li Y, Yan B, Zhu X, Liu X, Yang C, Xu J, Zhou G, Xu A, Li H, Liu Y (2014) A genome-wide association study identifies polymorphisms in the HLA-DR region associated with non-response to hepatitis B vaccination in Chinese Han populations. Hum Mol Genet 23:2210–2219
Saco T, Strauss A, Ledford D (2018) Hepatitis B vaccine nonresponders: possible mechanisms and solutions. Ann Allergy Asthma Immunol 121:320–327
Shouval D, Roggendorf H (2015) Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol 204:57–68
Shouval D, Ilan Y, Adler R, Deepen R, Panet A, Gorecki M, Gerlich W (1994) Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccines 12:1453–1459
Rendi-wagner P, Shouval D, Genton B, Lurie Y, Hans R, Boland G, Cerny A, Heim M, Bach D, Schroeder M, Kollaritsch H (2006) Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccines 24:2781–2789
Alon D, Stein G, Rn V, Tau L, Brosh T, Turner D (2017) Immunogenicity of Sci-B- vac (a third-generation hepatitis B vaccine) in HIV-positive adults. Isr Med Assoc J 19:143–146
Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife 1:e00049
Neurath A, Setot B, Strick N (1989) Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein, are virus-neutralizing and protective. Vaccines 4:35–37
Wolfert M, Boons G (2013) Adaptive immune activation: glycosylation does matter. Nat Chem Biol 9:776–784
Battagliotti J, Fontana D, Etcheverrigaray M, Prieto C (2020) Characterization of hepatitis B virus surface antigen particles expressed in stably transformed mammalian cell lines containing the large, middle and small surface protein. Antivir Res 183:104936
Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463–8471
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al (1996) In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector. Science 272:263–267
Prieto C, Fontana D, Etcheverrigaray M, Kratje R (2011) A strategy to obtain recombinant cell lines with high expression levels. Lentiviral vector-mediated transgenesis. BMC Proc 5(8):7
Hama S, Akita H, Ito R, Mizuguchi H, Hayakawa T, Harashima H (2006) Quantitative comparison of intracellular trafficking and nuclear transcription between adenoviral and lipoplex systems. Mol Ther 13:786–794
Varga C, Tedford N, Thomas M, Klibanov A, Griffith L, Lauffenburger D (2005) Quantitative comparison of polyethylenimine formulations and adenoviral vectors in terms of intracellular gene delivery processes. Gene Ther 12:1023–1032
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Battagliotti, J.M., Fontana, D., Etcheverrigaray, M., Kratje, R., Prieto, C. (2022). Development, Production, and Characterization of Hepatitis B Subviral Envelope Particles as a Third-Generation Vaccine. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 2410. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1884-4_13
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1884-4_13
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1883-7
Online ISBN: 978-1-0716-1884-4
eBook Packages: Springer Protocols